Point72 Hong Kong Ltd Purchases 4,893 Shares of Qiagen (NYSE:QGEN)

Point72 Hong Kong Ltd grew its stake in Qiagen (NYSE:QGEN) by 26.2% during the 2nd quarter, Holdings Channel.com reports. The firm owned 23,572 shares of the company’s stock after acquiring an additional 4,893 shares during the period. Point72 Hong Kong Ltd’s holdings in Qiagen were worth $969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Riverview Trust Co bought a new position in shares of Qiagen in the first quarter valued at about $28,000. Toronto Dominion Bank acquired a new stake in Qiagen during the second quarter worth about $27,000. Park Place Capital Corp acquired a new stake in Qiagen during the first quarter worth about $36,000. Quarry LP acquired a new stake in Qiagen during the fourth quarter worth about $38,000. Finally, CWM LLC grew its stake in Qiagen by 19.1% during the first quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after buying an additional 358 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Down 1.7 %

Shares of NYSE QGEN opened at $44.11 on Thursday. The company has a 50 day simple moving average of $45.06 and a 200 day simple moving average of $43.48. The firm has a market cap of $10.07 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million during the quarter, compared to analyst estimates of $495.45 million. During the same quarter last year, the business earned $0.53 EPS. The company’s revenue was down .2% compared to the same quarter last year. On average, research analysts forecast that Qiagen will post 2.15 EPS for the current year.

Analysts Set New Price Targets

QGEN has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Robert W. Baird raised their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a research note on Thursday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.10.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.